CareDx to Present AlloHeme Data at 2025 Tandem Meetings on Early Relapse Detection
CareDx, Inc. (Nasdaq: CDNA), a leader in precision medicine focused on transplant patients and caregivers, today announced the presentation of new AlloHeme data at the 2025 Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®, held February 12-15, 2025 in Honolulu, Hawaii.
CareDx, Inc. , a leading precision medicine company specializing in transplant care, presented new data on its AlloHeme™ test at the 2025 Tandem Meetings, the Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®, held February 12-15, 2025, in Honolulu, Hawaii. The data highlighted the results of the ACROBAT study, a multi-center, prospective trial assessing AlloHeme’s ability to monitor relapse after allogeneic stem cell transplantation in patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).
An oral presentation of the study shared the one-year interim analysis, which showed that AlloHeme is both an accurate and sensitive test for relapse monitoring. The test, by measuring small changes in mixed chimerism, demonstrated strong performance characteristics with a hazard ratio (HR) of 40.5 (p<0.001) for relapse detection. The analysis revealed a clinically meaningful median lead time of 36 days before relapse occurred, offering clinicians an early warning for intervention. The study cohort included 229 AML and MDS patients from 11 stem cell transplant centers across the U.S.
“We are extremely pleased with the results of the ACROBAT study, which demonstrate that AlloHeme is highly accurate in predicting relapse risk for patients who have undergone hematopoietic cell transplantation,” said Dr. Monzr M. Al Malki, Associate Professor and Director of the Unrelated Donor Bone Marrow Transplant Program at City of Hope National Medical Center. “This study takes us one step closer to having a reliable molecular biomarker that can assess stem cell engraftment status and predict relapse risk.”
AlloHeme, developed by CareDx, is a next-generation sequencing (NGS)-based test that has shown greater sensitivity than traditional methods for monitoring engraftment and relapse after allogeneic hematopoietic stem cell transplantation. This makes it a potentially critical tool for detecting relapse earlier, which is crucial for improving patient outcomes in hematologic malignancies.
“The interim results of the ACROBAT study align with our strategy to expand into hematology oncology,” said Marica Grskovic, PhD, Chief Strategy Officer at CareDx. “With AlloHeme, we can detect relapse earlier than conventional methods, providing clinicians with valuable lead time to intervene sooner. We are thrilled with the results demonstrating AlloHeme’s high sensitivity and honored that it was selected for an oral presentation at the Tandem Meetings, given the significant impact this data may have on patient outcomes through earlier malignancy detection.”
CareDx’s AlloHeme is designed to support clinicians in detecting relapse and monitoring post-transplant outcomes more effectively. By enabling earlier identification of relapse in AML and MDS patients, the test offers the potential to improve clinical decision-making and patient prognosis by allowing earlier interventions.
The ACROBAT study, with its focus on real-world clinical settings, validates AlloHeme as an important tool for transplant centers, offering a clear advantage over current standard of care methods. The study results contribute to the growing body of evidence supporting the use of AlloHeme in the early detection of hematologic malignancies after stem cell transplantation.
As the precision medicine field continues to evolve, CareDx remains committed to expanding its diagnostic and treatment solutions to improve the care of transplant patients. The company’s broad range of products, including AlloHeme, illustrates its leadership in providing high-value, clinically differentiated healthcare solutions for patients and caregivers across the transplant journey.
About CareDx – The Transplant Company
CareDx, Inc. is a precision medicine solutions company based in Brisbane, California, focused on improving the transplant patient journey. The company develops and commercializes clinically differentiated solutions that provide high-value healthcare for transplant patients and caregivers. CareDx offers a variety of testing services, products, and digital healthcare solutions, and is a leading provider of genomics-based information for transplant patients.
